DNA binding activities of p53 protein following cisplatin damage of ovarian cells

Oncology Research

Volumn 10, Issue 3, 1998, Pages 151-161

  Wetzel, Cynthia C ^a   Berberich, Steven J ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Cisplatin; Ovarian cells; P53 protein

Indexed keywords

CISPLATIN; DNA; DNA BINDING PROTEIN; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; CARCINOMA; CELL CULTURE; DNA ADDUCT; DRUG EFFECT; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR;

CARCINOMA; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031626830     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene. Nature 351: 453-456; 1991.
2. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 253: 49-53;1991.
3. Lane, D. P. p53, guardian of the genome. Nature 358: 15-16; 1992.
4. Ko, L. J.; Prives, C. p53: Puzzle and paradigm. Genes Dev. 10: 1054-1072; 1996.
5. El-Deiry, W. S.; Kern, S. E.; Pietenpol, J. A.; Kinzler, K. W.; Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49; 1992.
6. Zambetti, G. P.; Bargonetti, J.; Walker, K.; Prives, C.; Levine, A. J. Wild-type 53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6: 1143-1152; 1992.
7. Kastan, M. B.; Zhan, Q.; El-Deiry, W. S.; Carrier, F. T. J.; Walsh, W. V.; Plunkett, B. S.; Vogelstein, B.; Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia lelangiectasia. Cell 71: 587-597; 1992.
8. EI-Deiry, W. S.; Tokino, T.; Velculescu, V. W.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825; 1993.
9. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299; 1995.
10. Barak, Y.; Juven, T.; Haffner, R.; Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468; 1993.
11. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245; 1992.
12. Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565-1569; 1991.
13. Zauberman, A.; Flusberg, D.; Haupt, Y.; Barak, Y.; Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm-2 gene. Nucleic Acids Res. 23: 2584-2592; 1995.
14. Barak, Y.; Gottlieb, E.; Junve-Gershon, T.; Oren, M. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8: 1739-1749; 1994.
15. Mosner, J.; Deppert, W. p53 and mdm2 are expressed independently during cellulaf proliferation. Oncogene 9: 3321-3328; 1994.
16. Mayo, L. D.; Berberich, S. J. Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation. Oncogene 13: 2315-2321; 1996.
17. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126-1132; 1993.
18. Masuda, H.; Ozols, R. F.; Lai, G.; Fojo, A.; Rothenber, M.; Hamilton, T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48: 5713-5716; 1988.
19. Brown, R.; Clugston, C.; Burns, P.; Edlin, A.; Vasey, P.; Vojtesek, B.; Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55: 678-684; 1993.
20. Vaisman, A.; Varchenko, M.; Said, I.; Chaney, S. G. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64; 1997.
21. Siddik, Z. H.; Minis, B.; Lozano, G.; Thai, G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 58: 698-703; 1998.
22. Hupp, T. R.; Meek, D. W.; Midgley, C. A.; Lane, D. P. Regulation of the specific DNA binding function of p53. Cell 71: 875-886; 1992.
23. Hupp, T. R.; Spark, A.; Lane, D. P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-245; 1995.
24. Hainaut, P.; Milner, J.; Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53: 4469-4473; 1993.
25. Jayaraman, L.; Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029; 1995.
26. Jayaraman, L.; Murthy, K. G. K.; Zhu, C.; Curran, T.; Xanthoudakis, S.; Prives, C. Identificaton of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11: 558-570; 1997.
27. Ng, S.; Gunning, P.; Eddy, R.; Ponte, P.; Leavitt, J.; Shows, T.; Kedes, L. Evolution of the functional human β-actin gene and its multi-pseudogene family: Conservation of noncoding regions and chromosomal dispersion of pscudogenes. Mol. Cell. Biol. 5: 2720-2732; 1985.
28. Hinds, P. W.; Finlay, C. A.; Frey, A. B.; Levine, A. J. Immunologieal evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-rac-transformed cell lines. Mol. Cell. Biol. 7: 2863-2869; 1987.
29. Müller, U.; Roberts, M. P.; Engel, D. A.; Doerfler, W.; Shenk, T. Induction of transcription factor AP-1 by adenovirus ElA protein and cAMP. Genes Dev. 3: 1991-2002; 1989.
30. Turchi, J. J.; Li, M.; Henkels, K. M. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry 35: 2992-3000; 1996.
31. Perry, M. E.; Piette, J.; Zawadzke, J. A.; Harvey, D.; Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 90: 11623-11627; 1993.
32. Chen, C.-Y.; Oliner, J. D.; Zhan, Q.; Fornance, A. J.; Vogelstein, B.; Kastan, M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 91: 2648-2688; 1994.
33. Anthoney, D. A.; MxIlwrath, A. J.; Gallagher, W. M.; Edlin, A. R. M.; Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 56: 1374-1381; 1996.
34. Mymryk, J. S.; Zaniewski, E.; Archer, T. K. Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc. Natl. Acad. Sci. USA 92: 2076-2080; 1995.
35. Funk, W. D.; Pak, D. T.; Karas, R. H.; Wright, W. E.; Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12: 2866-2871; 1992.
36. McKay, R. D. G. Binding of a simian virus 40 T antigen-related protein to DNA. J. Mol. Biol. 145: 471-488; 1981.
37. Hansen, S.; Hupp, T. R.; Lane, D. P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J. Biol. Chem. 271: 3917-3924; 1996.
38. Wu, L.; Bayle, J. H.; Elenbaas, B.; Pavletich, N. P.; Levine, A. J. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15: 497-504; 1995.
39. Lee, S.; Elenbaas, B.; Levine, A.; Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020; 1995.
40. Reed, M.; Woclker, B.; Wang, P.; Wang, Y.; Anderson, M. E.; Teglmeyer, P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA 92: 9455-9459; 1995.
41. Hupp, T. R.; Lane, D. P. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinase. Cold Spring Harbor Symp. Quant. Biol. 59: 195-206; 1994.
42. Takenaka, I.; Morin, F.; Seizinger, B. R.; Kley, N. Regulation of the sequence-specific DNA binding function of p53 by protein kinasc C and protein phosphatases. J. Biol. Chem. 270: 5405-5411; 1995.
43. Gu, W.; Reeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606; 1997.
44. Molinari, M.; Okorokov, A. L.; Milner, J. Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa fragments competent for sequence-specific DNA bindina. Oncogene 13: 2077-2086; 1996.
45. Wu, Y.; Huang, H.; Miner, A.; Kulesz-Maritn, M. Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc. Natl. Acad. Sci. USA 94: 8982-8987; 1997.
46. Weinberg, W. C.; Azzoli, C. G.; Chapman, K.; Levine, A. J.; Yuspa, S. H. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10: 2271-2279; 1995.
47. WAF1 expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Mol. Cell. Biol. 18: 1400-1407; 1998.
48. Landers, J. E.; Cassel, S. L.; George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57: 3562-3568; 1997.
49. Saucedo, L. J.; Carstens, B. P.; Seavey, S. E.; Albee, L. D., II; Perry, M. E. Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation. Cell Growth Diff. 9: 119-130; 1998.